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Background
Sonic hedgehog (Shh) is a secreted protein known to func-
tion in the patterning of multiple regions of the embryo,
including the dorsoventral axis of the nervous system [1],
sclerotome formation in the somites [2], and anteroposte-
rior patterning of the limbs [3]. Shh gene mutations have
been described in both mouse [4] and human [5]. More-
over, the targeted disruption of Shh in mouse is lethal at or
around birth. In addition to loss of the ventral neural tube
throughout the neuraxis, there are significant defects in
head development in these Shh mutants. Facial structures
that are normally bilateral are fused and the branchial
arches, which are outgrowths of the head that contain endo-
derm, ectoderm, mesoderm and neural crest cells, fail to
develop. By embryonic day 15.5, the face is reduced to a
single fused structure in the midline [4]. Point mutations in
the human SHH gene have been linked to holoprosen-
cephaly, a heterogeneous disorder characterized by pertur-
bations in the development of the forebrain and midline of
the face [5]. It is unclear, however, whether the loss of head
structures that occurs when Shh is mutated is due to loss of
Shh expression in the ectoderm and endoderm of the devel-
oping head or is secondary to defects in the neural tube.
Neural crest cells play a central role in establishing and
patterning the head of the developing embryo. Neural
crest cells migrate from the dorsal neural tube, through
the cranial mesenchyme and into the branchial arches.
They contribute to formation of the forebrain meninges,
cranial sensory ganglia and some of the skull [6]; those
cells that enter the branchial arches contribute to forma-
tion of the bones of the jaw [7]. Ablation of the dorsal
neural tube, just before neural crest cell  migration, greatly
reduces the number of cranial neural crest cells. Interest-
ingly, embryos that are depleted of neural crest cells have
a phenotype similar to that of embryos with reduced Shh
signaling, including defects in the forebrain, cyclopia or
microopthalmia, and reduced size or absence of jaw struc-
tures derived from the neural crest [8–10]. No direct rela-
tionship between neural crest cells and Shh signaling has
yet been described, however. In fact, aside from its role in
dorsoventral patterning of the cranial neural tube, the role
of Shh in the development of the head remains unclear. 
In addition to its expression in the notochord and floor-
plate, Shh is expressed in a precise pattern in the ectoderm
and endoderm of the developing branchial arches during
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neural crest cell migration. Shh has been proposed to play
a role in pattern formation of the branchial arches that is
similar to its function in limb development [11,12]. In the
Shh mutant mouse, the branchial arches are lost [4], and in
chick embryos treated with alkaloids that block Shh sig-
naling, branchial arches are reduced [13,14]. Because both
of these approaches remove Shh signaling before ventral-
ization of the neural tube, the mechanism of loss of
branchial arch structures could be due either to the loss of
an inductive event, similar or identical to the induction of
floorplate, or could reflect a continuous requirement for
Shh in directing the patterning and/or growth of the
branchial arches. To distinguish between these two possi-
bilities, it is necessary to block Shh signaling at a later
stage, after the initial induction of floorplate. 
In order to examine the role of Shh in head patterning
subsequent to its role in patterning the neural tube, we
used antibody-mediated perturbation of Shh function
during branchial arch formation and population by migrat-
ing neural crest cells. We found that a reduction of Shh
signaling had severe consequences on head growth and
morphology. In particular, there was a reduction in the
survival of neural tube and neural crest cells, which led to
a loss of branchial arch structures and reduced head size. 
Results
Shh expression in the head during cranial neural crest cell
migration 
The pattern of Shh expression in the developing chick
head has been described previously [12]. Shh transcripts are
located in the floorplate cells of the neural tube as well as
in the axial mesoderm (prechordal mesoderm and noto-
chord), which underlies the floorplate (Figure 1a,h,
Figure 2). By developmental stage 12, Shh expression
begins in the lateral pockets of the pharyngeal endoderm,
which grow out to meet the ectoderm and form the
branchial arches (Figure 1a–c,h–i, Figure 2d,f). After 3 days
of incubation (stages 15–19), Shh expression is strong in the
branchial arches, but is restricted to specific patterns in
each branchial arch, and is confined to the ectoderm or
endoderm (Figure 1d,f, Figure 2). The pattern of expres-
sion of Patched (Ptc), the gene encoding the transmembrane
receptor for Shh, is similar to that of Shh at this stage
(Figure 1e,g), except that the expression domain extends
from the epithelium into adjacent mesenchymal cells. 
Cranial neural crest cells arise at a distance from the floor-
plate and actively avoid the notochord during migration
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Figure 1
Location of Shh mRNA and neural crest cells in the developing chick
head. (a–c) Shh expression in two-day-old embryos (stage 12).
(a) Dorsal view demonstrates Shh mRNA in the midline floorplate
(asterisk) and in more lateral regions of the head (arrows). (b) Lateral
view demonstrates that the lateral patch (arrow) is ventral to the otic
vesicle (OV). (c) Horizontal section through the lateral Shh-expressing
areas confirms that the signal is in the pharyngeal endoderm (PE).
(d–g) Shh and Ptc expression in a three-day-old embryo (stage 17).
(d) Shh mRNA is expressed in a specific pattern in each branchial arch
(I–III). (e) Ptc mRNA is expressed in a similar fashion. (f,g) Parasagittal
sections through the second branchial arch reveal that the Shh mRNA
is confined to the posterior edge of the arch, whereas Ptc mRNA is
more diffuse, extending into the mesenchyme. (h) Transverse section
taken just posterior to the otic vesicle in an embryo at stage 15. Shh
(green) is present in three locations — the floorplate, the notochord and
the pharyngeal endoderm (PE) — as detected by antibody staining.
Neural crest cells express the HNK-1 antigen (red). (i) An embryo that
received a quail-to-chick hindbrain graft at the seven-somite stage and
was subsequently immunostained, at stage 14, with an antibody
against a quail perinuclear marker, QCPN (green nuclear stain).
The antibody labels neural crest cells that have migrated past the
Shh-positive pharyngeal endoderm (PE, diffuse green surface labeling)
in this transverse section at the level of the second branchial arch. Current Biology   
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[15]; subsequently, these cells migrate past the Shh-express-
ing areas of the endoderm (Figures 1h,i). The HNK-1 anti-
body recognized a population of migratory neural crest cells
en route to the branchial arches (Figure 1h), but this
epitope was downregulated as the cells approached the
pharyngeal endoderm and entered the arch. To verify that
neural crest cells approach the pharyngeal endoderm, we
used quail-to-chick neural tube grafts to visualize neural
crest cells in the later stages of migration. The hindbrain of
a seven-somite host chick embryo (stage 9) was replaced
with a donor hindbrain from a quail embryo at the same
stage; migrating neural crest cells were recognized using the
quail-specific nuclear antibody, QCPN. By stage 14, quail
neural crest cells were observed migrating past the Shh-pos-
itive pharyngeal endoderm (Figure 1i).
Antibody-mediated inhibition of Shh signaling in the chick
head
We have previously shown that injection of hybridoma
cells into the head provides an efficient and continuous
source of function-perturbing antibody [16]. To test the
role of Shh in head patterning subsequent to its role in
floorplate specification and division of the eye field, we
introduced hybridoma cells (line 5E1) that block the func-
tion of Shh [17] into the mesenchyme lateral to the hind-
brain of embryos at stage 9–11 (Figure 2a). This resulted in
a continuous source of anti-Shh antibody. A quail-specific
antibody, QCPN, which has the same isotype, was used as
a control. This antibody recognizes a perinuclear antigen
present only in quail cells, and does not crossreact with
chick cells (Figure 2e,g). Injection of anti-Shh hybridoma
cells into the lateral mesenchyme allowed diffusion of the
antibody throughout the head of the embryo, including
access to the floorplate and endoderm (Figure 2d). 
The production and spread of the antibody as a function
of time was visualized using alkaline-phosphatase-conju-
gated secondary antibody (Figure 2). The antibody
strongly labeled Shh-expressing tissues, such as noto-
chord, floorplate, and pharyngeal endoderm, and lightly
labeled adjacent tissues known to express the Shh recep-
tor Ptc, such as the ventral and intermediate neural tube
(Figure 2f). The injected hybridoma cells survived and
proliferated (as judged by intact nuclei and BrdU incorpo-
ration, respectively; data not shown). No apparent differ-
ences were noted between unilateral and bilateral
injections, nor were there any apparent differences in the
hybridoma survival and proliferation between the control
and experimental hybridoma lines (data not shown). 
The pattern of antibody labeling was reproducible as a
function of time after injection. Two hours after injection,
the floorplate of the hindbrain was consistently labeled
adjacent to the injected cells (Figures 2b,c); by 6 hours
after injection, the ventral midline, notochord and pre-
chordal mesoderm throughout the head were labeled.
This suggests that the antibody diffuses and interacts
with all Shh-producing sites in the head. In contrast to
injections into the cranial mesenchyme lateral to the
neural tube, hybridoma cells introduced into the lumen of
the neural tube yielded staining that was confined to the
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Figure 2
Time course of staining after hybridoma injection. Cells were injected
adjacent to the developing hindbrain either (a,b) unilaterally or
(c–e) bilaterally. (a) At the time of injection, the cells can be seen as a
white mass in the lateral mesenchyme (arrow). (b) Whole-mount
immunohistochemistry 2 h after injection demonstrates the position of
the cells next to the hindbrain (arrow), and reveals neural-tube midline
staining. (c) A section through the hindbrain at the otic placode (OP)
reveals that the anti-Shh antibody labels the floorplate (FP) as well as
the hybridoma cells 2 h after injection. NC, notochord. (d) One day after
injection, the midline structures and the posterior second branchial arch
are all labeled with the anti-Shh antibody, as are the hybridoma cells
(arrow). Although confined to the head, antibody staining has spread
both rostrally and caudally from the injection site. (e) One day after
injection of hybridoma cells expressing the anti-quail antibody (control),
the antibody has labeled only the hybridoma cells themselves (arrow),
but has not spread or labeled the embryo as a whole. (f) Two days after
injection, the anti-Shh antibody strongly labels the floorplate (FP),
notochord (NC) and pharyngeal pouches (PP), and weakly labels the
intermediate neural tube and mesenchyme of the branchial arches
(Ba2). (g) In control-hybridoma-treated embryos, antibody only labels
the hybridoma cells, although it is occasionally trapped in other
structures, such as the otic vesicle (OV).
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floorplate (see later). This suggests that the antibody
cannot cross the neural tube basement membrane when
introduced lumenally. 
Shh transcripts are expressed in the pharyngeal endoderm
by ~stage 12, which corresponds to 9–15 hours after injec-
tion. Consistent with this, labeling of the endoderm with
anti-Shh antibody was observed only after 12 hours (data
not shown). Robust labeling in the endoderm and ecto-
derm of the branchial arch was observed 1 day after injec-
tion (Figures 2d,f). The cells producing the anti-Shh
antibody typically resided within the cranial mesenchyme,
but were occasionally found in the lumen of the develop-
ing pharynx (Figure 2c). In contrast to anti-Shh hybridoma,
control injections resulted in labeling of no structures other
than the hybridoma cells themselves (Figures 2e,g).
Developmental abnormalities after injection of anti-Shh
antibody
Both anti-Shh-treated and control embryos had developed
the same number of somites when examined at 6 and
24 hours after injection (Table 1). In contrast, profound
changes were observed in the progression of head devel-
opment by one day post-injection. Branchial arch forma-
tion was abnormal in anti-Shh-treated embryos, and an
analysis of head size 24 hours after treatment revealed a
significant size reduction of ~17–20% of anti-Shh-treated
embryos compared with control embryos (p < 0.05 in three
experiments, Student’s t-test; n = 35 and 28 for anti-Shh
and control embryos, respectively; Figure 3a–c).
There was a reduction in overall embryonic development
in anti-Shh-treated embryos compared with control
embryos 48 hours after hybridoma injection. By this stage,
the expressed antibody had diffused throughout the
embryo (data not shown). Many embryos appeared abnor-
mal or drastically delayed developmentally compared to
controls (Figure 3d,e), but there was no increase in embry-
onic mortality. The extensive abnormalities made it diffi-
cult to accurately compare head size between experimental
groups. Therefore, embryos were categorized on the basis
of the state of their developmental progression. Although
branchial arch morphology appeared grossly normal
24 hours after injection of hybridoma cells, a significant
percentage of the neural crest cells that normally populate
branchial arches did not survive in the absence of Shh sig-
naling (see below). This eventually resulted in regression
or arrest of branchial arch development, such that a high
percentage of embryos had a readily identifiable pheno-
type that consisted of reduced or missing branchial arch
structures and reduced frontonasal tissue when compared
to age-matched control embryos (Figure 3d). The forebrain
exhibited particularly poor development. The percentage
of embryos with these abnormal phenotypes was signifi-
cantly higher after anti-Shh treatment (n = 44) compared
with control (n = 36; χ2 = 10.834, p < 0.05; Figure 3d). 
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Table 1
Somite development after 6 and 24 h of hybridoma treatment.
Time after hybridoma injection Number of somites added
Anti-Shh Control
6 h* 2.5 ± 0.2 (n = 6) 2.7 ± 0.3 (n = 6)
24 h* 16.9 ± 0.4 (n = 8) 17.6 ± 0.3 (n = 12)
The asterisks indicate a probability (p) of > 0.05.
Figure 3
A reduction in head development is seen in embryos 1, 2 and 7 days
after treatment with the anti-Shh antibody. (a,b) Embryos were
collected one day after hybridoma injection and photographed at a fixed
magnification. Two measurements were made on each embryo: from
the anterior otic vesicle to the midbrain (D–C) and from the nose to the
hindbrain (A–B). (c) The measurements demonstrate a significant
reduction (p < 0.05; asterisk) in the size of the head in both dimensions
measured (n = 35 and 28 for anti-Shh and control embryos,
respectively; three experiments). (d) Two days after injection, there was
a population of dramatically smaller embryos, with a reduction in
branchial arch development. (e) Significantly more abnormally small
embryos were seen after anti-Shh treatment, with no increase in embryo
mortality (n = 44 and 36 for anti-Shh and control embryos, respectively).
(f) A control embryo that was injected with QCPN hybridoma cells at
stage 10 displayed no abnormalities.(g–i) Embryos that survived for
7 days after anti-Shh treatment had holoprosencephaly and/or impaired
growth. (g) An embryo that was injected with anti-Shh hybridoma cells
at stage 10. (h,i) Two views of the most severe phenotype found in
these experiments after anti-Shh hybridoma injections. Two separate,
although rudimentary, eyes are present (arrowheads). The upper and
lower beak form, although they are small. All pictures were taken at the
same magnification. The scalebar represents 1 mm. 
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Long-term embryonic survival after hybridoma treatment
was low regardless of the hybridoma cell type used (data
not shown). Increases in mortality began on the third day
after hybridoma injection, presumably because of an over-
proliferation of the hybridoma cells or a toxic effect of
having hybridoma cells in the developing embryo (3 days
after injection, 23.5% of control embryos were alive, com-
pared with 23.7% of anti-Shh-treated embryos). 
Some embryos (< 5%) survived for up to 7 days after
injection. These embryos appeared to have normal pat-
terning of the cartilaginous skeleton (n = 4; data not
shown), although head size was reduced in anti-
Shh-injected embryos, compared with control-injected
embryos (Figure 3f,g). Of twelve anti-Shh embryos,
two had severe holoprosencephaly, but not cyclopia
(Figure 3h,i), whereas surviving control embryos dis-
played no abnormalities (Figure 3f). Embryos with severe
brain and eye phenotypes possessed upper and lower
jaws that were normally patterned but reduced in size
(Figure 3h), which is consistent with the findings that loss
of neural crest cells in this region was not complete, as
suggested by the analysis of cell death one day after
injection (see below). 
Analysis of cell proliferation after antibody injection
Shh is thought to play multiple roles in cell proliferation
and differentiation [18–21]. The reduced head size after
anti-Shh treatment could be due to decreased proliferation
and/or increased cell death. To determine whether anti-
Shh treatment affects cell proliferation, embryos were
exposed to BrdU for 1 hour at two different times after
injection. A reduction in BrdU labeling of ventral neural
tube cells was observed 6 hours after anti-Shh hybridoma
injection in seven out of nine embryos (data not shown).
This effect was confined to cells in the immediate vicinity
of the injected hybridoma cells. In contrast, other regions
of the neural tube within the same section did not appear
to be affected. The proliferation of cells in the mes-
enchyme, even those adjacent to hybridoma cells, also
appeared to be unaffected. In contrast to anti-Shh-treated
embryos, no change in proliferation was seen in twelve
control embryos examined (see Supplementary material).
This initial reduction in proliferation of neural tube cells
was transient and was not maintained in embryos exam-
ined 1 day after treatment with anti-Shh hybridoma cells,
when no significant differences were observed in the per-
centage of BrdU-positive cells in anti-Shh-treated, com-
pared with control embryos (Table 2). The transient and
localized decrease in proliferation within the neural tube
6 hours after injection appears to be insufficient to account
for the smaller head size in anti-Shh-treated embryos.
Analysis of cell death after hybridoma injection
Another mechanism that can result in fewer cells and
smaller tissues is cell death, either due to active killing as
observed in the thymus, or apoptosis in response to
limited amounts of survival factors. Cell death was exam-
ined in whole embryos using the membrane-impermeable
dye benzothiazolium-4-quinolium (TO-PRO-1) [22]. Only
a minor amount of cell death, scattered throughout the
head, was seen in control embryos (Figure 4c). But, exten-
sive cell death was observed 24 hours after treatment with
anti-Shh hybridoma (Figure 4a,b). The pattern of dying
cells was reminiscent of migratory streams of neural crest
cells around the otic vesicle. 
To examine cell death at the level of individual cells, sec-
tions were exposed to the nuclear stain 4′,6-diamidino-2-
phenylindole (DAPI) [23]. Live cells had diffuse nuclear
staining after DAPI staining, whereas dead cells had con-
densed, bright staining (Figure 4d–g,5). Separate sections
were stained using the TUNEL method, which confirmed
that the pyknotic nuclei seen with DAPI are also TUNEL-
positive (data not shown). No differences in the amount of
cell death were observed in anti-Shh-treated embryos
examined 6 hours after injection, compared with control
embryos (data not shown). When examined 24 hours after
injection, increased cell death in both the neural tube
(Figure 4f) and the mesenchyme (Figure 4d) was seen in
anti-Shh-treated embryos compared with control embryos
(Figure 4e,g). In contrast, no increase in cell death was
seen in the adjacent ectoderm, notochord, and the otic
vesicle (Figure 4d). The percentage of dead cells in the
neural tube in anti-Shh-treated embryos was significantly
greater than in control embryos (5.7 ± 1.6%, n = 37 com-
pared with 0.4 ± 0.2, n = 30; p < 0.05).
Many dying cells within the cranial mesenchyme are of
neural crest origin
To determine whether the dead cells in the mesenchyme
are of neural crest origin, embryonic sections were
stained with the HNK-1 antibody, which labels the
majority of cranial neural crest cells during the early
stages of their migration. In contrast to cranial neural
crest cells, cranial mesenchyme cells are HNK-1-negative
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Table 2
BrdU incorporation after 24 h of hybridoma treatment.
BrdU-positive cells (%)
Anti-Shh Control
Mesenchyme* 46.0 ± 1.7 (n = 76) 51.8 ± 2.5 (n = 28)
Neural tube* 46.1 ± 2.0 (n = 37) 45.5 ± 2.3 (n = 26)
The asterisks indicate a probability (p) of > 0.05; numbers in
parentheses refer to the number of sections examined; twelve anti-
Shh-treated embryos and six control embryos were examined.
(Figure 5b). Sections were co-stained with DAPI to
determine the percentage of dead cells in each region
(Figure 5a), as assayed by their pyknotic nuclei. 
Cell counts revealed a significant increase in cell death
in the HNK-1-positive regions of the mesenchyme fol-
lowing treatment with anti-Shh hybridoma cells
(Figure 5c). Because the membranes of dying cells
remain intact for some time after initiation of the apop-
totic cascade, it was possible to visualize condensed
DAPI nuclei in cells with HNK-1-positive membranes.
Some pyknotic nuclei were associated with HNK-1-posi-
tive membranes under these conditions (Figure 5a,b).
Visualization of individual neural crest cells was facili-
tated by a reduction of neural crest cell numbers by
partial ablation of the dorsal neural tube at stage 10
(Figures 5d,e), after which, single cells with an apoptotic
profile were readily observed to have HNK-1-positive
membranes. Cell counts after partial ablation revealed
that of 320 dead cells observed 1 day after anti-Shh
hybridoma injection, 100 possessed HNK-1-positive cell-
surface staining. That the dead cells in the mesenchyme
were likely to be neural crest cells was suggested by
several observations: first, their position in streams next
to the hindbrain corresponding to areas rich in neural
crest cells, which contain few other mesenchymal cells
(Figures 4a,b); second, the observation that the cell
membranes of dying cells stained with the HNK-1 anti-
body (Figure 5); and third, the paucity of dying cells in
regions without neural crest cells (Figure 5).
Relationship between cell death in the neural tube and cell
death in the neural crest
Because cell death was seen in both the neural tube and
the neural crest, it was germane to ask whether neural
crest cell death was secondary to cell death in the neural
tube. To this end, we examined neural crest cell survival
under two different circumstances: after ablation of the
dorsal or the entire neural tube; and after injection of
anti-Shh hybridoma cells into the neural tube lumen,
which blocks Shh in the neural tube but not in the noto-
chord or endoderm. 
Ablation of the hindbrain dorsal neural tube after neural
crest cells had migrated (8–12 somite embryos) did not
result in significant cell death of HNK-1-positive neural
crest cells in the absence of anti-Shh treatment (1.4 ± 0.23%;
n = 54 sections, five embryos). Even ablation of the entire
neural tube and notochord (in 12–15 somite embryos) did
not result in significant death of the neural crest cells that
were already migrating (2.02 ± 0.8%, n = three embryos;
Figure 6a–c). Sham ablations did not result in significant
changes in neural crest cell death (data not shown).
Injection of anti-Shh hybridoma cells into the neural tube
resulted in confinement of antibody to the neural tube, as
judged by immunohistochemistry (n = five embryos;
Figure 6d), thus blocking Shh signaling only in the floor-
plate. This led to cell death in the neural tube itself (data
not shown), but little cell death in the HNK-1-positive
neural crest cells (4.61 ± 1.04%, n = 29 sections from
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Figure 4
Anti-Shh antibody increases cell death.
(a–c) TOPRO-1, a membrane-impermeable
dye, reveals cell death after anti-Shh
treatment. (a) An embryo one day after
injection of anti-Shh antibody displays cell
death in many regions of the head, including
streams around the otic vesicle (asterisk in
(a–c)). Note that this embryo had very little
development of the branchial arches.
(b) Closer view of the streams, characteristic
of neural crest migratory pathways, around
the otic vesicle. (c) Very little cell death is
seen in a control embryo, which has a well-
developed second branchial arch (Ba2).
(d–g) Examples of cell death, as seen by
DAPI staining, in the (d,e) mesenchyme and
(f,g) neural tube of (e,g) control and
(d,f) anti-Shh-treated embryos. (d,e) are
sections through the anterior edge of the
otic vesicle, and (f,g) are sections from the
anterior hindbrain. Arrows in (d) and (f) point
to pyknotic nuclei, and the arrowhead in
(f) indicates a hybridoma cell nucleus.
The asterisk indicates the position of the
otic vesicle. DA, dorsal aorta; PP,
pharyngeal pouches. 
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four embryos; compare with Figure 5c). Thus, cell death in
the dorsal neural tube is separable from cell death in the
migrating neural crest cell population, suggesting that
neural crest cells are not dying as a secondary consequence
of cell death in the dorsal neural tube. Consistent with
this, head size was not altered under these conditions.
The average distance between the otic vesicle and mid-
brain was 1.59 ± 0.092 mm (n = 9) in anti-Shh-treated
embryos compared with 1.58 ± 0.086 mm (n = 28) in
control embryos. Similarly, the average distance between
the nose and hindbrain was 1.83 ± 0.086 mm (n = 9) in anti-
Shh-treated embryos compared with 1.81 ± 0.094 mm
(n = 28) in the controls. Taken together with the ablation
experiments, these results indicate that the absence of the
neural tube (by ablation) or cell death (after hybridoma
injection) can account for only a small part of the survival
signal initiated by Shh, which ultimately affects migrating
neural crest cells. In addition, the normal head size observed
after injection of hybridoma cells into the neural tube indi-
cates that cell death of neural crest cells is requisite for the
smaller heads seen after lateral hybridoma injection.
Discussion
Sonic hedgehog is well recognized as an inductive signal
for the formation of ventral midline of the neural tube and
posterior limb bud, but its role in cell survival and prolifer-
ation has not been fully appreciated. We demonstrate that
reducing Shh signaling has a dramatic effect on develop-
ment of the cranial neural tube and branchial arches, pri-
marily because of increased cell death, which leads to an
overall reduction in head size. Two hours after injection
into the head mesenchyme, floorplate cells bound anti-
Shh antibody. There was no apparent loss of floorplate,
however, even in severely affected embryos (data not
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Figure 5
Dead cells in the mesenchyme are neural crest cells. Sections were
stained for HNK-1 and DAPI, and the percentages of pyknotic nuclei in
HNK-1-positive and HNK-1-negative areas were determined.
(a,b) Representative sections from an embryo treated with anti-Shh
hybridoma cells. The line denotes the edge of the HNK-1-positive cells;
arrows point to pyknotic nuclei in (a) and to the corresponding HNK-1-
positive membrane in (b). Large asterisks indicate vessels used for
alignment. (c) There was a significant increase in the number of dying
cells in the regions that labeled with the HNK-1 antibody (HNK-1+)
after treatment with anti-Shh (p < 0.001), but no increase in the
number of dying HNK-1-negative (HNK-1–) mesenchymal cells.
(d,e) After dorsal neural tube ablation, the number of neural crest cells
are reduced. In this embryo, treated with anti-Shh hybridoma cells,
(e) a small cluster of neural crest cells lie adjacent to the neural tube.
Within this cluster, five distinct pyknotic nuclei can be seen, and four of
these have readily identifiable HNK-1-positive membranes (arrows).
One cell with condensed DNA, indicated by the arrowhead in (d), does
not appear to have any HNK-1 membranes associated with it, as
indicated by the small asterisk in (e).
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Figure 6
Loss of the neural tube does not lead to cell
death in the neural crest. (a–c) Ablation of
the entire neural tube and notochord at stage
11 does not result in cell death in the neural
crest cells that have already migrated.
(a) Section through the hindbrain region in
which the neural tube was ablated. A small
otic vesicle (OV) has formed dorsally on one
side of the embryo. PP, pharyngeal pouch.
(b) Higher magnification view of the region
next to the pharyngeal pouch does not
demonstrate any significant number of
pyknotic nuclei. (c) HNK-1 staining
demonstrates that neural crest cells fill this
region of the embryo. (d) Injection of
hybridoma cells into the lumen of the neural
tube at stage 9–10 results in the staining
being confined to the floorplate (FP). 
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shown), confirming that ventral midline induction has
occurred by this stage. Furthermore, the presence of the
blocking antibody did not prevent the subsequent expres-
sion of Shh by the pharyngeal endoderm.
Previous experiments have examined the effect of reduc-
ing or removing Shh early in development. Shh null mice
have a variety of defects, including the loss of branchial
arches and their derivatives [4]. Treatment of chick
embryos at stage 4 with Shh-blocking alkaloid inhibitors
results in a variety of head phenotypes, including com-
plete cyclopia, which is thought to occur when the eye
field fails to divide under the influence of the prechordal
plate [13,14]. Both the mouse and chicken phenotypes
have been likened to the human developmental defect
holoprosencephaly, the most severe cases having cyclopia
[24]. Cyclopia was not observed in our study, presumably
because bilateral eye fields have already separated by the
time of Shh perturbation, or because insufficient neural
crest cells are deleted by this treatment. Neither cyclopia
nor head size reduction were seen with a single alkaloid
treatment initiated at stage 10 rather than stage 4 (our
unpublished observations) [13]. But multiple injections of
cyclopamine into avian embryos starting at stage 10
resulted in a reduction in head size that was similar to
that seen with function-blocking antibodies (our unpub-
lished observations).
The loss of facial structures in the Shh mutant mouse and
the craniofacial phenotypes of humans with holoprosen-
cephaly cannot be completely reconciled with a simple
loss of midline neural tube signaling. Neural crest cell
death following inhibition of Shh signaling might explain
the loss of the branchial arches and frontonasal mass
tissues seen in the mouse knockout, and the facial dys-
morphism seen in some of the patients with loss of a
single copy of SHH. Reducing Shh signaling after the
establishment of bilateral head structures still results in
significant defects. This indicates that there is a continued
requirement for Shh signaling in the growth and develop-
ment of the head. Our results suggest that Shh might play
two important roles in neural tube development — an
early patterning role and a later proliferative/survival func-
tion. This does not, however, rule out subsequent roles for
Shh in head development and patterning [25].
The surviving neural crest cells appeared to contribute to
the formation of structures derived from the neural crest,
such as mandible and maxilla, because these were visible
in the surviving older embryos. These were smaller both
in the short term (1 day after injection) and in the long
term (7 days after injection) suggesting that, although the
residual neural crest cells patterned the facial structures
correctly (Figure 3), they did not compensate for the early
reduction in cell number. Thus, the reduction in head
size was probably due to inadequate numbers of neural
crest cells, rather than to a developmental delay or other
patterning effect.
Because the decrease in head size correlates with signifi-
cant death of neural crest cells, the neural crest appears to
be the primary determinant of head size at the stage
examined. Given that the neural crest comprises most of
the skeletal elements of the face, this is not unexpected.
Noden [26] has shown that neural crest cells are responsi-
ble for patterning the head mesoderm. Neural crest cells
might not only pattern the mesodermal cells of the head,
but might also be involved in coordinating their size to
match that of neural-crest-derived structures. Such coor-
dinate regulation of cell number in the control of tissue
size probably occurs through a combination of cell prolif-
eration and survival [27]. Cell death in the neural tube
alone was not sufficient to account for the decrease in
head size 24 hours after hybridoma injection, although it
undoubtedly played a role in the decreased head size at
later timepoints.
There is a precedent for Shh being involved in the control
of cell proliferation and cell survival [18–21]. The noto-
chord secretes factors (including Shh) that are responsible,
not only for the organization of ventral cell types, but also
for cell proliferation and survival. Notochord grafts next to
chick neural tubes result in increased neuroblast prolifera-
tion [28], whereas genetic or surgical removal of the noto-
chord results in cell death in the neural tube [29,30].
Thus, the role of Shh in the proliferation of the ventral
neural tube is not unexpected, given the role that Shh
plays in the control of cell fate of ventral progenitors
[17,31,32]. The transient block of proliferation in the
neural tube was restricted to ventral cells whereas the cell
death was seen primarily in dorsal neural tube cells, sug-
gesting that two separate cell types are affected by anti-
Shh treatment in the neural tube. Death of dorsal neural
tube cells might indicate that these cells directly need Shh
to survive, which is consistent with their expression of the
receptor gene Ptc [33]. To date, cell death in the neural
tube and neural crest has not been reported for the Shh
mutant mouse.
During normal development, many cell types are pro-
duced in excess and later eliminated by cell death result-
ing from a competition for survival factors [27]. Although
we do not yet know whether Shh acts directly as a survival
factor for migrating cranial neural crest cells, the finding
that the reduction of Shh signal with blocking antibodies
results in neural crest cell death suggests that Shh func-
tions, either directly or indirectly, to regulate survival
within this population. Unlike dorsal neural tube cells,
early migrating cranial neural crest cells do not express
either of the vertebrate Ptc genes [34,35], although the
second receptor component, encoded by Smoothened
(Smo), is ubiquitously expressed at low levels in most
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tissues during development [36]. Expression of Ptc in pre-
sumptive neural crest cells can only be seen at stages
equivalent to those seen on the second day after injection
(Figure 1g), when, in normal embryos, Ptc is expressed in
the mesenchyme of the branchial arch, in cells likely to be
of neural crest origin. The Gli zinc-finger gene family is
implicated in transduction of Shh signals, but these factors
appear to be absent from migrating cranial neural crest
cells [37]. This raises two interesting possibilities: first,
that there are other molecules required for Shh signaling
present in migrating cranial neural crest; or second, Shh
effects on neural crest occur through an intermediate
mechanism, possibly by regulating the expression of other
survival or growth factors. Experiments described in this
paper eliminate the neural tube as the source of survival
factors for migrating neural crest cells, because removal of
the neural tube and notochord after initiation of neural
crest migration does not result in cell death of the migrat-
ing neural crest cells.
Cell death has not been previously described for migrating
cranial neural crest, although both premigratory dorsal
neural tube crest progenitors and postmigratory crest cell
derivatives have been shown to die under a variety of con-
ditions. In the hindbrain, it has been suggested that premi-
gratory neural crest cells in rhombomeres three and five
are depleted by apoptotic signals from adjacent, even-
numbered rhombomeres [38]. The neural crest cell death
described here is not the same, because anti-Shh treat-
ment resulted in neural crest cell death all along the
cranial neural axis, and in the streams of neural crest adja-
cent to the even-numbered rhombomeres (Figure 4a).
Mutant mice that lack both Wnt-1 and Wnt3a have reduced
numbers of neural crest cells, but this reduction results
from either a lack of proliferation or a cell death event that
happens prior to neural crest migration [39]. Loss of AP-2,
a transcription factor expressed in cranial neural crest cells,
also results in cranial neural crest cell death, but of post-
migratory neural crest cell populations [40,41]. 
Conclusions
Our data demonstrate that the anti-Shh antibody, applied
after ventral midline induction, can phenocopy some of
the notable features of holoprosencephaly, including pro-
found reductions in head size. We show that the likely
cause of the reduced head size is cell death of cranial
neural crest cells during their migration to the branchial
arches. Because neural crest cells are important for pat-
terning the cranial mesoderm, we propose that the initial
loss of neural crest cells might subsequently affect the size
of structures in the head derived from the mesoderm and
from the neural tube. These experiments are novel in that
they establish, for the first time, that the severe loss of
facial structures in holoprosencephaly are likely to result
from a combination of effects of Shh on neural crest cells
as well as an early effect on the ventral midline. Thus, our
data show that Shh is involved in proliferation and survival
of the cranial neural tube and neural crest. By acting to
control cell division and survival in a variety of cell types
in the head, Shh plays an important role in governing head
size in addition to its well known role in patterning parts
of the head. The data presented here provide a link
between the cyclopia seen with a variety of defects in Shh
signaling [4,13,14] and the cyclopia seen when cranial
neural crest cells are ablated [8–10].
Materials and methods
Cell culture
Hybridoma cells (both anti-Shh and QCPN) were obtained from the
Developmental Studies Hybridoma Bank (Iowa City). Cells were grown
in Isocoves modified media (Gibco) supplemented with 20% heat-inac-
tivated fetal bovine serum and penicillin–streptomycin. Both antibodies
used in this study are subtype IgG1. 
Embryos
White Leghorn chicken eggs were incubated in a rocking incubator at
37°C with constant humidity until stages 9–11 (7–14 somite stage) of
development [42]. A glass needle was placed at the midbrain–hind-
brain level, and cells were pressure injected into the lateral head mes-
enchyme or into the neural tube. Ablations were performed on embryos
at the 8–15 somite stage, using a fine glass needle to remove the
desired area (dorsal neural tube or entire neural tube with or without
the notochord). For quail-to-chick chimeras, the neural tube was
ablated at the 7 somite stage, and then a quail neural tube of the same
age was put in place, followed 4–6 h later with placement of the
hybridoma cells. In all cases, the eggs were sealed with tape and
replaced in a non-rocking incubator.
Whole-mount in situ hybridization
Whole-mount in situ hybridizations were performed as described
previously [43]. 
Head measurements
Embryos were collected and fixed at the desired time. The embryos
were photographed at a fixed magnification on a dissecting micro-
scope (Zeiss), with a calibrated graticule photographed at the same
magnification. The measurements were made blind to treatment group
by projecting slides of individual embryos on a screen, measuring the
head dimensions, and converting the measurements using the graticule
as a standard.
Fixation, whole-mount immunohistochemistry and sectioning 
Embryos were fixed in 4% paraformaldehyde, rinsed, dehydrated in
100% methanol and stored at –20°. After rehydration, the embryos
were bleached, rinsed and treated with proteinase K, refixed and
blocked in 10% sheep serum. The secondary antibody used for whole-
mount immunohistochemistry was an alkaline-phosphatase-linked rabbit
anti-mouse IgG1 (Zymed), which was diluted 1:500 for use. The pres-
ence of the secondary antibody was detected using NBT/BCIP reaction
product. For sectioning, embryos were immersed in a solution compris-
ing 15% sucrose and 7.5% gelatin in PBS and then frozen. For immuno-
histochemistry, embryos were sectioned at –28°C, at 10–12 µm. 
BrdU and cell death
Embryos were exposed to 10–2 M 5-bromo-2′-deoxyuridine (BrdU;
Sigma). Sections were processed for BrdU as described previously
[44]. Sections were then counterstained with 10 µg/ml of the nuclear
marker 4′,6-diamidino-2-phenylindole (DAPI; Sigma) in H2O for 10 min,
and then mounted under a coverslip with Gel/Mount (Biomedia). 
To detect cell death in live embryos, embryos were stained with a 1:50
solution of the membrane-impermeant dye, TO-PRO-1 iodide in DMEM
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(Molecular Probes) for 30 min at 37°C, followed by three washes in
DMEM. The embryos were then visualized using a scanning confocal
microscope (Biorad). 
To determine the percentage of cell death in the neural crest, sections
were stained with FITC-linked goat anti-mouse IgG (to localize
hybridoma cells and visualize antibody spread), followed by 1:1 HNK-1
supernatant and then TRITC-goat anti mouse IgM. All antibodies were
diluted in PBS/BSA. Sections were then counterstained with DAPI as
described above. Pyknotic nuclei were counted relative to live nuclei
with only clearly condensed or fragmented nuclei counted as dead.
Supplementary material
Supplementary material, including figures showing neural tube prolifer-
ation after anti-Shh treatment and the effects of hybridoma injection
into the lateral mesenchyme or neural tube, is available at
http://current-biology.com/supmat/supmatin.htm.
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Figure S1
Neural tube proliferation is reduced with anti-Shh treatment. (a) There
are local reductions in cell proliferation in the neural tube 6 h after
injection of hybridoma cells expressing the anti-Shh antibody. After
treatment with anti-Shh, there are regions of BrdU-negative neural tube
(indicated by brackets). The FITC-conjugated anti-IgG1 secondary
antibody used recognizes both the anti-BrdU and the anti-Shh
antibody. Thus, the injected hybridoma cells are the larger green cells
(arrows) and the floorplate and notochord are brightly labeled. This
loss of proliferation, either bilaterally or unilaterally, was seen in seven
out of nine embryos examined 6 h after hybridoma injection. (b) No
regional loss of BrdU was seen in control embryos (none out of six
embryos examined). Arrows point to hybridoma cells.
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Figure S2
Comparison between lateral -mesenchyme and neural-tube injections.
(a) Measurement of the head size 1 day after injection of hybridoma
cells demonstrates no decrease in head size when hybridoma cells are
placed in the neural tube, compared with the control. In contrast, a
decrease in head size is seen when hybridoma cells are injected into
the lateral mesenchyme. (b) Measurements of cell death demonstrate
that both sites of injection are equally efficient at causing neural tube
cell death; however, lateral injections are twofold more efficient at
causing neural crest (HNK-1+) cell death. In (a) n = 35, 10 and 28, and
in (b) n = 61, 28 and 63 for lateral injection, neural-tube injection and
control, respectively.
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